Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Profounda, Inc. ("Profounda") announced today that it has received the US Food and Drug Administration's Orphan Drug Designation Approval for the use ...
Profounda, Inc. ("Profounda") announced today that it has received the US Food and Drug Administration's Competitive Generic Therapy (CGT)...
Profounda, Inc. ("Profounda") announced today that Rhinase® Baby Lubricating Nasal Drops is now available in the United States through Rhinase.com...
Profounda, Inc. ("Profounda") announced today that it has received the US Food and Drug Administration's Orphan Drug Designation for the use of...
Profounda, Inc. ("Profounda") announced today that it has received, the US Food and Drug Administration's (FDA) Orphan Drug Designation for the...
Profounda, Inc. ("Profounda") announced today that the drug Impavido® (miltefosine) was used to successfully treat 16 year old patient Sebastian...
Profounda, Inc. ("Profounda") announced today that Rhinase® is now available in the United States immediately on Rhinase.com and Amazon.com. Today,...
Profounda, Inc. ("Profounda") announced today that Impavido® (miltefosine) is now available in the United States. Impavido is the first and only oral ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.